Piper Sandler Raises Madrigal Pharmaceuticals (NASDAQ:MDGL) Price Target to $336.00

Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) had its price objective hoisted by equities researchers at Piper Sandler from $305.00 to $336.00 in a research note issued to investors on Wednesday, Benzinga reports. The brokerage currently has an “overweight” rating on the biopharmaceutical company’s stock. Piper Sandler’s price target suggests a potential upside of 45.91% […]

Related Keywords

United States ,Piper Sandler ,Roberte Waltermire ,Osaic Holdings Inc ,News Ratings For Madrigal Pharmaceuticals Daily ,Exchange Traded Concepts ,Montaga Associates Inc ,Securities Exchange Commission ,Russell Investments Group Ltd ,Madrigal Pharmaceuticals ,Analyst Recommendations For Madrigal Pharmaceuticals ,Institutional Investors Weigh In On Madrigal Pharmaceuticals ,Madrigal Pharmaceuticals Inc ,Madrigal Pharmaceuticals Company Profile ,Madrigal Pharmaceuticals Price Performance ,Global Retirement Partners ,Get Free Report ,Advisors Lp Baker ,Exchange Commission ,Retirement Partners ,Traded Concepts ,Investments Group ,Osaic Holdings ,Madrigal Pharmaceuticals Daily ,Nasdaq Mdgl ,Mdgl ,Medical ,87162t20 ,Boost Price Target ,